No clear answer
Baclofen: improve symptoms or function in MS (type not specified)
MS (type not specified) · Spasticity
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 2
These linked trials do not set the status.
Phase 3 · 2016 · Compared with baclofen
Phase 3 · 2007 · Compared with baclofen
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as No clear answer
Related hypotheses
- Spasticity: improve symptoms or function in MS (type not specified)
- Arbaclofen: improve symptoms or function in MS (type not specified)
- Botulinum toxin type a: improve symptoms or function in MS (type not specified)
- Cannabidiol: improve symptoms or function in MS (type not specified)
- Dronabinol: improve symptoms or function in MS (type not specified)
- Nabilone: improve symptoms or function in MS (type not specified)
- Nabiximols: improve symptoms or function in MS (type not specified)
- Onabotulinumtoxina: improve symptoms or function in MS (type not specified)
- Rimabotulinumtoxinb: improve symptoms or function in MS (type not specified)
- Tizanidine: improve symptoms or function in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error